Josep M. Llovet, MD, PhD, discusses the evolution of treatment options for patients with hepatocellular carcinoma.
Josep M. Llovet, MD, PhD, founder and director of the Liver Cancer Program at Mount Sinai School of Medicine in New York and professor of research in the Liver Unit at the University of Barcelona, discusses the evolution of treatment options for patients with hepatocellular carcinoma (HCC). Sorafenib (Nexavar) has remained the standard of care and only treatment option for these patients prior to recent findings.
Previously, sorafenib (Nexavar) was the only treatment option for newly diagnosed patients and remained the standard of care for many years. Lenvatinib (Lenvima) has since demonstrated similar benefits to sorafenib in the frontline setting in patients with HCC in a noninferiority trial.
In the last 3 years, there has been an evolution in terms of new agents for the second-line setting in HCC. Regorafenib (Stivarga), cabozantinib (Cabometyx), and ramucirumab (Cyramza) have also been introduced into the treatment landscape. All 3 agents have been investigated and proven effective in phase III clinical trials compared towith placebo for patients with HCC.
In the frontline setting, lenvatinib (Lenvima) has also demonstrated similar benefit to sorafenib in patients with HCC. Overall, there have been a number of new agents introduced to the treatment landscape, says Llovet.